ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1560

Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

Martina Bonacini1, Francesco Muratore1, Giovanna Restuccia2, Laura Albertazzi2, Piera Zaldini2, Luca Cimino3, Rossana Colla2, Alessandro Zerbini1, Carlo Salvarani4 and Stefania Croci1, 1Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, 3Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, cytokines, Cytotoxic Cells, Natural Killer Cells, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are commonly used for BD management [Hatemi G. Ann Rheum Dis 2018]. NKG2D is a receptor expressed by NK, NKT and CD8 T cells that acts as a sensor for self antigens induced by infections, stress and neoplastic transformation [Lanier LL. Cancer Immunol Res 2015]. We have demonstrated that BD patients are characterized by higher NKG2Dpos NK, NKT and T cells [Bonacini M. Front Immunol 2018]. We hypothesized that following NKG2D increase, BD patients are more prone to respond to NKG2D ligands, which could lead to cyclic auto-inflammation. Drugs able to inhibit NKG2D expression might thus be the most promising in BD patients. The aims of the present work were to: 1) evaluate the effects in vitro on NKG2D expression by immune cells of drugs used for BD management, epigenetic drugs and nutraceuticals; 2) determine if the effects differed between BD patients and controls (CTR); 3) analyse circulating levels of NKG2D ligands.

Methods: Peripheral Blood Mononuclear Cells (PBMCs) from 5 active BD patients naive from therapy and 5 CTR were treated for 48h with 500 ng/ml Dexamethasone (Dexa) or 3000U interferon α-2A or 1µM Colchicine or 30µM Aza or 250µM iBet-762 or 730µM Valproic Acid or 5µM Curcumin. NK (CD56posCD3neg), NKT (CD56posCD3pos), CD8 T (CD56negCD3posCD8pos) cell percentages and NKG2D levels on their surface were evaluated by flow cytometry. To mimic the active phase of the disease, PBMCs were treated with IL-15 for 24h followed by drugs treatment for additional 48h in presence of IL-15. The same analyses were performed. The levels of NKG2D soluble ligands were quantified in plasma of 11 active BD patients naive from therapy and 22 CTR. For 7 BD patients,plasma during the active and inactive phases were analysed.

Results: Unstimulated PBMCs from BD patients cultured with Dexa showed a reduction in NK cell percentages. Conversely, Dexa increased NK cells percentages in activated PBMCs. All the treatments reduced NKG2D expression on NK, NKT and CD8 T cells, with the exception of interferon α-2A treatment that did not modify NKG2D levels on unstimulated PBMCs. Similar effects were observed after treatment of PBMCs from BD and CTR. Higher concentrations of soluble MICA, one of the ligands of NKG2D, were observed in plasma from active BD patients than CTR. MICA levels decreased in BD patients who progressed from active to inactive phase.

Conclusion: BD patients were characterized by higher soluble MICA that increases the possibility of immune cell activation. Drugs commonly used for BD management were able to down-regulate NKG2D levels on immune cells surface, reducing their activation capacity. In addition drugs used for the treatment of other diseases, such as Valproic Acid used for breast cancer and iBet-762 used for pancreatic cancer, showed the same effects on NKG2D expression. The reduction of NKG2D expression on immune cells induced by the drugs was independent of the BD condition. This should be considered when treating patients in whom it is important to maintain the immune surveillance, such as cancer patients.


Disclosures: M. Bonacini, None; F. Muratore, None; G. Restuccia, None; L. Albertazzi, None; P. Zaldini, None; L. Cimino, None; R. Colla, None; A. Zerbini, None; C. Salvarani, None; S. Croci, None.

To cite this abstract in AMA style:

Bonacini M, Muratore F, Restuccia G, Albertazzi L, Zaldini P, Cimino L, Colla R, Zerbini A, Salvarani C, Croci S. Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/modulation-of-nkg2d-expression-on-nk-nkt-and-cd8-t-lymphocytes-by-in-vitro-treatments-of-immune-cells-from-patients-with-behcet-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modulation-of-nkg2d-expression-on-nk-nkt-and-cd8-t-lymphocytes-by-in-vitro-treatments-of-immune-cells-from-patients-with-behcet-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology